Skip to main
ORIC

Oric Pharmaceuticals (ORIC) Stock Forecast & Price Target

Oric Pharmaceuticals (ORIC) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company with a diverse pipeline of therapies targeting resistance mechanisms in cancer. The company's focus on hormone-dependent cancers, precision oncology, and key tumor dependencies, paired with a 35-40% probability of approval for its lead candidates in various cancer indications, presents a strong investment opportunity. Risks include clinical failure, delays in pivotal trials, and slower market uptake, but a discounted cash flow-based valuation yields a price objective of $25 per share.

Bears say

ORIC Pharmaceuticals is facing two main challenges that may have contributed to the recent decline in its stock price: the voluntary withdrawal of Tazverik from the market due to safety concerns and delays in clinical trials. However, these issues may be specific to Tazverik and not indicative of the company's overall pipeline. With promising data from its other product candidates and a strong balance sheet, investors could see a buying opportunity at the current dip in the stock price.

Oric Pharmaceuticals (ORIC) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Oric Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Oric Pharmaceuticals (ORIC) Forecast

Analysts have given Oric Pharmaceuticals (ORIC) a Buy based on their latest research and market trends.

According to 10 analysts, Oric Pharmaceuticals (ORIC) has a Buy consensus rating as of May 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Oric Pharmaceuticals (ORIC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.